🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Intuitive Surgical stock hits 52-week high at $525

Published 06/11/2024, 14:48
Updated 06/11/2024, 14:53
ISRG
-

Intuitive Surgical Inc . (NASDAQ:ISRG) has reached a significant milestone, with its stock price soaring to a 52-week high of $525. This impressive peak reflects a robust period of growth for the company, which has seen its stock value surge by 86.77% over the past year. Investors have shown increasing confidence in Intuitive Surgical's market position and its innovative robotic-assisted surgical technologies, which continue to gain traction in the healthcare industry. The company's strong performance and the rising demand for minimally invasive surgery solutions have contributed to this notable 52-week high, signaling a positive outlook for Intuitive Surgical's future.

In other recent news, Intuitive Surgical has reported a strong third quarter for 2024, with an 18% rise in DaVinci procedures and robust system placements. The company's revenue reached $2 billion, marking a 17% year-over-year increase. Piper Sandler, RBC Capital Markets, and Mizuho (NYSE:MFG) Securities have all adjusted their stock price targets for Intuitive Surgical following these results, maintaining their respective Overweight, Outperform, and Neutral ratings.

The company has also revised its full-year 2024 procedure growth forecast to 16-17%, up from the previous forecast of 15.5-17.0%. Intuitive Surgical's da Vinci (EPA:SGEF) 5 system placements were notably strong, with 110 new systems placed in the third quarter.

Despite pricing pressures in China, the company anticipates a broad launch of its next-generation system, DaVinci 5, by mid-2025. Moreover, Intuitive Surgical is focusing on expanding the Ion system internationally, particularly in China and Europe. These are the recent developments for the company.

InvestingPro Insights

Intuitive Surgical's recent stock performance aligns with several key metrics and insights from InvestingPro. The company's market capitalization stands at an impressive $184.94 billion, underscoring its significant presence in the medical technology sector. InvestingPro data reveals that ISRG's revenue grew by 14.83% over the last twelve months, with a notable 16.88% quarterly growth in Q3 2024, reflecting the strong demand for its robotic-assisted surgical systems.

The company's financial health is further emphasized by its robust gross profit margin of 66.98% and an operating income margin of 26.24%, indicating efficient operations and pricing power. These figures support the stock's impressive 85.81% total return over the past year, as mentioned in the article.

InvestingPro Tips highlight that 16 analysts have revised their earnings upwards for the upcoming period, suggesting positive expectations for ISRG's future performance. Additionally, the stock is trading near its 52-week high, which aligns with the article's mention of the recent peak price.

It's worth noting that while ISRG is showing strong growth and profitability, it is trading at high valuation multiples. This includes a P/E ratio of 81.31 and a Price / Book ratio of 11.77, indicating that investors are pricing in significant future growth expectations.

For readers interested in a deeper analysis, InvestingPro offers 17 additional tips for Intuitive Surgical, providing a comprehensive view of the company's financial position and market outlook.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.